Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 508

according to a recent study.

Type 2 diabetes is associated with excess risk for kidney stones. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase urine output and alter urine composition in ways that might lower risk for kidney stones. In this U.S. study, researchers compared risks for kidney stones among 600,000 adults with type 2 diabetes who were new users of SGLT-2 inhibitors versus 600,000 propensity score–matched patients who initiated glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which do not have the same renal effects.

During median follow-up of 6 months, risk for kidney stones was significantly lower in patients who began using SGLT-2 inhibitors than in patients who began using GLP-1 receptor agonists (15 vs. 22 events/1000 person-years) or DPP-4 inhibitors (15 vs. 20 events/1000 person-years). The effect was larger for younger patients (age, 70).

This study suggests that initiating SGLT-2 inhibitors, compared with GLP-1 receptor agonists or DPP-4 inhibitors, is associated with lower risk for kidney stones in the short term; whether this effect will persist long term is unknown. For a patient in whom the decision to start an SGLT-2 inhibitor (vs. another diabetes drug) is otherwise a toss-up, a history of recurrent kidney stones might tip the balance toward the SGLT-2 inhibitor.

Read more | >

The first human patient has received an implant from Neuralink, Elon Musk’s computer-brain interface company. Andrew Chang explores the complexity of the N1 implant, how it’s working in clinical trials, and what Neuralink is trying to achieve with the device.

»»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS

Connect with CBC News Online:

For breaking news, video, audio and in-depth coverage: http://bit.ly/1Z0m6iX
Follow CBC News on TikTok: https://bit.ly/3TnHioe.
Follow CBC News on Twitter: http://bit.ly/1sA5P9H
Find CBC News on Facebook: http://bit.ly/1WjG36m.
Follow CBC News on Instagram: http://bit.ly/1Z0iE7O

Download the CBC News app for iOS: http://apple.co/25mpsUz.
Download the CBC News app for Android: http://bit.ly/1XxuozZ

»»»»»»»»»»»»»»»»»»

Continue reading “Neuralink brain chip’s first human patient. How does it work? | About That” | >

A Chinese team of life scientists, microbiologists, plant researchers and seed designers has developed a way to grow engineered moss with partially synthetic genes. In their project, reported in the journal Nature Plants, the group engineered a moss that is one of the first living things to have multiple cells carrying a partially artificial chromosome.

Several research projects have been working toward the goal of creating plants with synthetic —such plants could be programmed to produce more food, for example, or more oxygen, or to pull more from the air. Last year, one team of researchers developed a way to program up to half of the genome of yeast cells using synthetic genes.

In this new effort, the team in China upped the ante by replacing natural genes with genes created in a lab—moss is far more genetically complex than yeast. They call their project SynMoss.

Read more | >

A new study claims that low-frequency ultrasound can reverse aspects of replicative and chemically induced senescence in vitro [1].

The age-related increase in senescent cell burden is thought to contribute to many processes of aging. Most of the attempts to deal with it involve senolytics: drugs that eliminate senescent cells.

However, it may be possible to re-educate them instead. Senomorphics are compounds that change senescent cells in a way that renders them benign, but they are much less common. The authors of this new pre-print study (it has not yet been peer-reviewed) claim to have found an even more impressive way to solve the senescent cell problem: by rejuvenating them with ultrasound.

Read more | >

Cells in the human body contain power-generating mitochondria, each with their own mtDNA—a unique set of genetic instructions entirely separate from the cell’s nuclear DNA that mitochondria use to create life-giving energy. When mtDNA remains where it belongs (inside of mitochondria), it sustains both mitochondrial and cellular health—but when it goes where it doesn’t belong, it can initiate an immune response that promotes inflammation.

Now, Salk scientists and collaborators at UC San Diego have discovered a novel mechanism used to remove improperly functioning mtDNA from inside to outside the mitochondria. When this happens, the mtDNA gets flagged as foreign DNA and activates a normally used to promote to rid the cell of pathogens, like viruses.

The findings, published in Nature Cell Biology, offer many new targets for therapeutics to disrupt the inflammatory pathway and therefore mitigate inflammation during aging and diseases, like lupus or rheumatoid arthritis.

Read more | >

A technique can determine for the first time how frequently, and exactly where, a molecular event called “backtracking” occurs throughout the genetic material (genome) of any species, a new study shows.

Published online February 9 in Molecular Cell, the study results support the theory that backtracking represents a widespread form of gene regulation, which influences thousands of , including many involved in basic life processes like and development in the womb.

Led by researchers from NYU Grossman School of Medicine, the work revolves around genes, the stretches of DNA molecular “letters” arranged in a certain order (sequence) to encode the blueprints for most organisms. In both humans and bacteria, the first step in a gene’s expression, transcription, proceeds as a protein “machine” called RNA polymerase II ticks down the DNA chain, reading genetic instructions in one direction.

Read more | >

An advanced human heart organoid system can be used to model embryonic heart development under pregestational diabetes-like conditions, researchers report in the journal Stem Cell Reports.

The organoids recapitulate hallmarks of pregestational diabetes-induced congenital heart disease found in mice and humans. The findings also showed that (ER) stress and lipid imbalance are critical factors contributing to these disorders, which could be ameliorated with exposure to omega-3s.

“The new stem cell-based organoid technology employed will enable physiologically relevant studies in humans, allowing us to bypass animal models and obtain more information about relevant disease mechanisms, accelerating drug discovery and medical translation,” says senior study author Aitor Aguirre of Michigan State University.

Read more | >

Histopathology describes the process of examining pieces of tissue using a microscope. Light microscopic (LM) examination of tissue helps diagnose several types of cancer by allowing pathologists to view cellular changes within a biopsy sample.

The workload of pathologists has increased in recent years due to policies that encourage screening for early cancer diagnoses. In addition, longer life expectancies and scientific advances have led to an increased number of cancer survivors, further increasing the need for pathology evaluations. Thus, strategies to efficiently utilize the limited pathology resources have become essential to maintaining standards of care and the health and safety of patients.

Digital pathology (DP) has emerged as an alternative method for analyzing tissue samples by stitching together digital images from histopathology slides. Automated slide scanners can rapidly generate these high-resolution images with minimal human interaction. In addition to the speed, DP does not require a microscope, offering remote viewing possibilities. Pathologists and other healthcare professionals can easily share images.

Read more | >